Skip Navigation


JAC Advance Access originally published online on February 11, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/3/613    most recent
dkg127v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Upton, A.
Right arrow Articles by Heffernan, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Upton, A.
Right arrow Articles by Heffernan, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 613-617
© 2003 The British Society for Antimicrobial Chemotherapy

Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance

A. Upton1,*, S. Lang2 and H. Heffernan3

1 Department of Infectious Diseases, Auckland Hospital, Private Bag 92024, Auckland; 2 Department of Microbiology, Middlemore Hospital, Auckland; 3 Antibiotic Reference Laboratory, Institute of Environmental Science and Research, Wellington, New Zealand

Received 21 October 2002, returned 21 November 2002, revised 16 December 2002; accepted 17 December 2002

Objectives: To describe trends in mupirocin resistance among Staphylococcus aureus in New Zealand (NZ), following the availability of mupirocin in 1986.

Patients and methods: Data from a variety of sources were used for this study: susceptibility data collected annually from diagnostic laboratories throughout NZ; a local survey of mupirocin-resistant S. aureus in the Auckland area in 1997; a national survey of S. aureus antimicrobial susceptibility in 1999; and the national methicillin-resistant S. aureus (MRSA) surveillance programme.

Results: All data sources show that there was a steady increase in mupirocin resistance among S. aureus throughout the 1990s, and rates in NZ are now markedly higher than those reported in most other comparable countries. By 1999, resistance averaged 28%, with higher rates among community-acquired compared with hospital-acquired isolates, and with a wide geographical variation in resistance. Resistance was more common among S. aureus generally than MRSA.

Conclusion: We postulate that the steady rise in mupirocin resistance among S. aureus in NZ throughout the 1990s may be due, at least in part, to the over the counter availability of mupirocin from 1991 to 2000. The current patterns of mupirocin consumption need to be reviewed and its use rationalized to maximize the chances of this antibiotic retaining beneficial antistaphylococcal activity.

Keywords: mupirocin, Staphylococcus aureus, resistance

* Corresponding author. Tel: +64-9-378-7440; Fax: +64-9-307-4940; E-mail: ArloU{at}adhb.govt.nz


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
X. Malaviolle, C. Nonhoff, O. Denis, S. Rottiers, and M. J. Struelens
Evaluation of disc diffusion methods and Vitek 2 automated system for testing susceptibility to mupirocin in Staphylococcus aureus
J. Antimicrob. Chemother., September 1, 2008; (2008) dkn345v1.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. E. Simor, T. L. Stuart, L. Louie, C. Watt, M. Ofner-Agostini, D. Gravel, M. Mulvey, M. Loeb, A. McGeer, E. Bryce, et al.
Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals
Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3880 - 3886.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Perez-Roth, C. Lopez-Aguilar, J. Alcoba-Florez, and S. Mendez-Alvarez
High-Level Mupirocin Resistance within Methicillin-Resistant Staphylococcus aureus Pandemic Lineages.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3207 - 3211.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. C. Schaffer, R. M. Solinga, J. Cocchiaro, M. Portoles, K. B. Kiser, A. Risley, S. M. Randall, V. Valtulina, P. Speziale, E. Walsh, et al.
Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model
Infect. Immun., April 1, 2006; 74(4): 2145 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. S. Rouse, M. Rotger, K. E. Piper, J. M. Steckelberg, M. Scholz, J. Andrews, and R. Patel
In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against Staphylococcus aureus
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3187 - 3191.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
E. S. Walker, F. Levy, M. Shorman, G. David, J. Abdalla, and F. A. Sarubbi
A Decline in Mupirocin Resistance in Methicillin-Resistant Staphylococcus aureus Accompanied Administrative Control of Prescriptions
J. Clin. Microbiol., June 1, 2004; 42(6): 2792 - 2795.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.